EHDN2020

Previous Meeting EHDN2020

virtual bridging EHDN banner

When: September 11, 2020 Time: 14:00 – 18:15 CET

View the programme

Q&A from the meeting (uploaded November 10, 2020)

Recorded sessions:
Welcome and introduction

Anne Rosser
Astri Arnesen
Patrick Weydt

Scientific progress session

  • Chair: Lesley Jones
  • Function of HTT – Frédéric Saudou
  • Somatic expansion of the HTT CAG repeat – Darren Monckton
  • HTT phosphorylation and TBK1 – Hilal Lashuel
  • Oral HTT-lowering therapy – George McAllister
  • Q&A and Discussion
Clinical studies session – PART 1

  • Chair: Jean-Marc Burgunder
  • An Update from the Tominersen Global Clinical Development Programme – Sarah Tabrizi
  • PRECISION HD1 and 2: allele selective targeting of the mutant HTT – Anna Heinzmann
  • Shield-HD – Anne Rosser
  • Prilenia – Bernhard Landwehrmeyer
  • First Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest HD – Ralf Reilmann
Clinical studies session – PART 2

  • Chair: Jean-Marc Burgunder
  • MIG-HD trial – Anne-Catherine Bachoud-Levi
  • HEATED- Huntington’s Equal Access to Effective Drugs – Hugh Rickards
  • Q&A and Discussion
Closing remarks

Bernhard Landwehrmeyer
Anne Rosser